Kannan Shruthi, Vedia Rolando A, Molldrem Jeffrey J
Department of Hematopoietic Biology and Malignancy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant (ECLIPSE), Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Front Immunol. 2024 Sep 16;15:1419807. doi: 10.3389/fimmu.2024.1419807. eCollection 2024.
This mini review summarizes the immunobiology of myelodysplastic syndromes, specifically focusing on the interactions between immune cells, cytokines, and dysplastic cells within the tumor microenvironment in the bone marrow. We elucidate in detail how immune dysregulation and evasion influence the initiation and progression of myelodysplastic syndromes, as well as resistance to therapy and progression to AML. In addition, we highlight a range of therapeutic strategies, including the most recent breakthroughs and experimental therapies for treating MDS. Finally, we address the existing knowledge gaps in the understanding of the immunobiology of MDS and propose future research directions, promising advancements toward enhancing clinical outcomes and survival for patients with MDS.
本综述总结了骨髓增生异常综合征的免疫生物学,特别关注骨髓肿瘤微环境中免疫细胞、细胞因子和发育异常细胞之间的相互作用。我们详细阐述了免疫失调和逃逸如何影响骨髓增生异常综合征的发生和进展,以及对治疗的抵抗和向急性髓系白血病的进展。此外,我们强调了一系列治疗策略,包括治疗骨髓增生异常综合征的最新突破和实验性疗法。最后,我们阐述了在骨髓增生异常综合征免疫生物学理解方面存在的知识空白,并提出了未来的研究方向,有望在改善骨髓增生异常综合征患者的临床结局和生存率方面取得进展。